ArticleJugan geon-gang gwa jilbyeong2024
[Support for Coronavirus Disease 2019 Comparator Vaccines and Research Vaccines].
Article in Jugan geon-gang gwa jilbyeong, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protecting people's health and lives through vaccination is crucial in the event of an infectious disease such as coronavirus disease 2019 (COVID-19). Vaccines are a cost-effective way of preventing infectious diseases and their spread. The absence of domestic companies capable of rapidly developing and supplying vaccines that are effective in responding to infectious diseases can lead to supply and demand instability and disruption of smooth vaccination owing to increasing external dependence on vaccine supplies. Therefore, it is necessary to support domestic companies and research institutes that are developing vaccines, so that effective and safe vaccines can be quickly and stably supplied to prevent infectious diseases. To support domestic pharmaceutical companies and research institutes that are researching and developing COVID-19 follow-up vaccines, this article will explain the overall project to provide free comparator vaccines from clinical trials and from research studies by using the surplus of the COVID-19 vaccines purchased by the government, as well as the achievements, limitations, and improvement plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.